Insider Transactions in Q2 2024 at Pacira Bio Sciences, Inc. (PCRX)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 28
2024
|
Jonathan Slonin Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
437
+0.44%
|
$10,488
$24.32 P/Share
|
|
Jun 28
2024
|
Daryl Gaugler Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
160
+0.14%
|
$3,840
$24.32 P/Share
|
|
Jun 13
2024
|
Kristen Marie Williams Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
7,452
-6.75%
|
$208,656
$28.38 P/Share
|
|
Jun 13
2024
|
Paul J Hastings Director |
SELL
Open market or private sale
|
Direct |
880
-6.47%
|
$24,640
$28.38 P/Share
|
|
Jun 13
2024
|
Daryl Gaugler Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,000
-0.85%
|
$28,000
$28.38 P/Share
|
|
Jun 12
2024
|
Marcelo Bigal Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,230
+50.0%
|
-
|
|
Jun 12
2024
|
Christopher Christie Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,230
+33.27%
|
-
|
|
Jun 12
2024
|
Jonathan Slonin Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,300
+35.45%
|
-
|
|
Jun 12
2024
|
Lauren Bullaro Riker Senior Vice President, Finance |
SELL
Open market or private sale
|
Direct |
3,970
-9.44%
|
$111,160
$28.72 P/Share
|
|
Jun 12
2024
|
Lauren Bullaro Riker Senior Vice President, Finance |
BUY
Grant, award, or other acquisition
|
Direct |
21,360
+33.69%
|
-
|
|
Jun 12
2024
|
Mark A. Kronenfeld Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,230
+17.36%
|
-
|
|
Jun 12
2024
|
Laura Brege Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,230
+24.01%
|
-
|
|
Jun 12
2024
|
Kristen Marie Williams Chief Administrative Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,300
+32.98%
|
-
|
|
Jun 12
2024
|
Paul J Hastings Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,230
+27.77%
|
-
|
|
Jun 12
2024
|
Alethia Young Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,230
+50.0%
|
-
|
|
Jun 12
2024
|
Mark Froimson Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,230
+28.57%
|
-
|
|
Jun 12
2024
|
Daryl Gaugler Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,300
+31.69%
|
-
|
|
Jun 12
2024
|
Abraham Ceesay Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,230
+50.0%
|
-
|
|
Jun 12
2024
|
Michael J. Yang Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,230
+50.0%
|
-
|
|
Jun 12
2024
|
Charles A. Reinhart Iii Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,220
+19.07%
|
-
|
|
Jun 11
2024
|
Jonathan Slonin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,012
-10.11%
|
$140,336
$28.57 P/Share
|
|
Jun 03
2024
|
Kristen Marie Williams Chief Administrative Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,011
-5.1%
|
$90,330
$30.89 P/Share
|
|
Jun 03
2024
|
Charles A. Reinhart Iii Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,979
-6.99%
|
$89,370
$30.89 P/Share
|
|
Jun 03
2024
|
Lauren Bullaro Riker Senior Vice President, Finance |
SELL
Payment of exercise price or tax liability
|
Direct |
1,843
-8.18%
|
$55,290
$30.89 P/Share
|
|
Jun 03
2024
|
Jonathan Slonin Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,615
-3.15%
|
$48,450
$30.89 P/Share
|
|
Jun 03
2024
|
Daryl Gaugler Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,754
-4.21%
|
$82,620
$30.89 P/Share
|